Prazepam

Prazepam
Clinical data
Other names	9-chloro-2-(cyclopropylmethyl)-6-phenyl-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen- 3-one
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601036
Routes of; administration	Oral
ATC code	N05BA11 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule IV; DE: Prescription only (Anlage III for higher doses); US: Schedule IV;
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	36–200 hours
Excretion	Renal
Identifiers
	IUPAC name 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one;
CAS Number	2955-38-6 ;
PubChem CID	4890;
IUPHAR/BPS	7275;
DrugBank	DB01588 ;
ChemSpider	4721 ;
UNII	Q30VCC064M;
KEGG	D00470 ;
ChEMBL	ChEMBL969 ;
CompTox Dashboard (EPA)	DTXSID4021181 ;
ECHA InfoCard	100.019.069
Chemical and physical data
Formula	C19H17ClN2O
Molar mass	324.81 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc4cc\1c(N(C(=O)C/N=C/1c2ccccc2)CC3CC3)cc4;
	InChI InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2 ; Key:MWQCHHACWWAQLJ-UHFFFAOYSA-N ;
	(verify)

Prazepam is a benzodiazepine derivative drug developed by Warner-Lambert in the 1960s.^[2] It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.^[3] Prazepam is a prodrug for desmethyldiazepam which is responsible for the therapeutic effects of prazepam.^[4]

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ US Patent 3192199 – Process for the production of I-CYCLO- ALKYL derivatives of I,X-BENZODIAZEPINE
^ Shader RI, Greenblatt DJ (1979). "Benzodiazepines: some aspects of their clinical pharmacology". Ciba Foundation Symposium. Novartis Foundation Symposia. 1979 (74): 141–155. doi:10.1002/9780470720578.ch9. ISBN 9780470720578. PMID 45081.
^ Jacqmin P, Ansseau M (1988). "Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data". Neuropsychobiology. 19 (4): 186–191. doi:10.1159/000118458. PMID 2854609.